The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...